Journal of Diabetes and Its Complications xxx (xxxx) xxx



Contents lists available at ScienceDirect

### Journal of Diabetes and Its Complications



journal homepage: WWW.JDCJOURNAL.COM

# A systematic review considering risk factors for mortality of patients discharged from hospital with a diagnosis of diabetes

Teesta Mukherjee <sup>a,1</sup>, Tim Robbins <sup>a,b,1</sup>, Sarah N. Lim Choi Keung <sup>a</sup>, Sailesh Sankar <sup>b,c</sup>, Harpal Randeva <sup>b,c</sup>, Theodoros N. Arvanitis <sup>b,\*</sup>

<sup>a</sup> Institute of Digital Healthcare, WMG, University of Warwick, Coventry CV4 7AL, United Kingdom

<sup>b</sup> University Hospitals Coventry & Warwickshire NHS Trust, Clifford Bridge Road, Coventry CV2 2DX, United Kingdom

<sup>c</sup> Warwick Medical School, University of Warwick, Coventry CV4 7AL, United Kingdom

#### ARTICLE INFO

Article history: Received 15 May 2020 Received in revised form 16 July 2020 Accepted 30 July 2020 Available online xxxx

Keywords: Diabetes Mortality Inpatient care Systematic review

#### ABSTRACT

*Aim:* To identify known risk factors for mortality for adult patients, discharged from hospital with diabetes. *Method:* The systematic review was based on the PRISMA protocol. Studies were identified through EMBASE & MEDLINE databases. The inclusion criteria were papers that were published over the last 6 years, in English language, and focused on risk factors of mortality in adult patients with diabetes, after they were discharged from hospitals. This was followed by data extraction "with quality assessment and semi-quantitative synthesis according to PRISMA guidelines".

*Results:* There were 35 studies identified, considering risk factors relating to mortality for patients, discharged from hospital with diabetes. These studies are distributed internationally. 48 distinct statistically significant risk factors for mortality can be identified. Risk factors can be grouped into the following categories; demographic, socioeconomic, lifestyle, patient medical, inpatient stay, medication related, laboratory results, and gylcaemic status. These risk factors can be further divided into risk factors identified in generalized populations of patients with diabetes, compared to specific sub-populations of people with diabetes.

*Conclusion:* A relatively small number of studies have considered risk factors relating to mortality for patients, discharged from hospital with a diagnosis of diabetes. Mortality is an important outcome, when considering discharge from hospital with diabetes. However, there has only been limited consideration within the research literature.

© 2020 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).

#### Contents

1.	Introduction	. 0
2.	Methods	. 0
	2.1. Search strategy	. 0
	2.2. Study selection	. 0
	2.3. Data extraction	. 0
	2.4. Quality assessment	. 0
	2.5. Data synthesis	. 0
3.	Results	. 0
	3.1. Search results	. 0
	3.2. Study characteristics	. 0
	3.3. Risk factor identification	. 0
	3.4. Study quality	. 0
4.	Discussion	. 0
5.	Conclusions	. 0

E-mail address: t.arvanitis@warwick.ac.uk (T.N. Arvanitis).

<sup>1</sup>Authors contributed equally.

https://doi.org/10.1016/j.jdiacomp.2020.107705

1056-8727/© 2020 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

<sup>\*</sup> Corresponding author.

### 

#### 1. Introduction

2

Patients with diabetes are known to be at an increased risk of complications and mortality during their inpatient stay.<sup>1,2</sup> Significant research and resource has been invested into understanding how to reduce this burden of inpatient mortality for patients with diabetes.<sup>3,4</sup> There has been much less focus on the risk of mortality, following discharge from hospital with diabetes. Data available on post discharge outcomes, in this patient population, is not abundant and is ambiguous.<sup>5</sup> There is evidence of an increased risk of mortality for patients with diabetes; however, tools for predicting mortality in such patients are not easily available.<sup>6</sup> This study, therefore, aims to systematically identify the known risk factors for mortality in patients with diabetes, after they are discharged from hospitals.

This work builds on a previous published work, considering risk factors for readmission of patients discharged from hospital with diabetes.<sup>7</sup> Readmission is a commonly considered measure of care quality, when patients are discharged from hospital, and, therefore, has been more closely studied than mortality following hospital discharge, arguably due to financial incentives and costs associated with readmission rates.<sup>8</sup> Both readmission and mortality are, however, important outcome measures, when considering the discharge of patients with diabetes and the subsequent development of risk prediction models. The consideration of which patients are at a greatest risk of mortality, following discharge, will help allocated limited resources to supporting this population.

The identification of risk factors, in this manner, has the potential to support research that enables us to predict mortality in patients with diabetes, following hospital discharge. Once risk factors are known and understood, they can be identified in the patient's individual Electronic Health Record (EHR). Understanding risk factors, relevant to patients discharged from hospital with diabetes, is important to patients, carers, healthcare practitioners and researchers. It supports the delivery and development of individualised medicine, based on each patient's underlying risks; supports our understanding of regional variations in readmission risk; and, supports development of evidence based interventions, targeted at reducing readmission risks. Interestingly, the paucity of research in this area, for diabetes, is in direct contrast to other medical conditions, such as heart failure.<sup>9</sup>

0

0

#### 2. Methods

#### 2.1. Search strategy

The systematic review was performed according to the PRISMA protocol.<sup>10</sup> The PRISMA flowchart is shown in Fig. 1.

#### 2.2. Study selection

The literature search was conducted in the MEDLINE, EMBASE & Engineering Village databases. Search terms used to identify relevant medical literature were (("diabetes" AND "discharge")) AND ("mortality" or "death" or "died"). Filters were applied to identify studies that were published, in English language, over the last 6 years (March 2014 to February 2020), to include the most recent clinical evidence available in this area of research. Additionally, filters were applied to set participants'



#### T. Mukherjee et al. / Journal of Diabetes and Its Complications xxx (xxxx) xxx

#### Table 1

\*Comprising of: 10 retrospective cohort, 4 retrospective analysis, 2 retrospective case control, 1 retrospective observational 1 retrospective registry and 1 retrospective risk prediction modeling.

Study design	Number of papers	Percentage of papers (%)
Retrospective study*	19	54
Prospective study	10	29
Registry based	5	14
Post hoc analysis	1	3

age as 18 years and above, as this research looked at only adult patients. Any study that focused on in-hospital mortality or diabetes, as a risk factor for other clinical conditions, was excluded.

#### 2.3. Data extraction

Data was extracted to a pre-determined, data-extraction proforma. Data was extracted based on the following variables; year of publication, type of study, location of research, sample size, sub population of people with diabetes, statistically significant risk factors and statistical tests for analysis. Additionally, risk factors not meeting significance criteria, but had impact were also extracted. Data extraction was performed independently by two authors, with any discrepancies resolved by a third author.

#### 2.4. Quality assessment

All studies included in the review were assessed for study quality. Data was extracted using Keshav's 5Cs (category, context, correctness, contribution and clarity),<sup>11</sup> alongside sample size, justification of their participant selection and statistical tests applied. Papers were not excluded based on producing a negative outcome or being a low quality study.

#### 2.5. Data synthesis

The diversity among the identified studies, in terms of their sample sizes and patient population with various co-morbidities apart from diabetes, did not allow a meta-analysis to be conducted. Instead, both a semi-quantitative and narrative summary of identified prognostic risk factors were performed. Individual risk factors have then been grouped under broader categories, as and when necessary.

Table 2		
D'	C · 1	

Distribution of study geographies.

Study location	# studies	Study location	# studies	Study location	# studies
United States Australia	3 2	Canada China	1 1	Spain Middle East	1 1
Brazil	2	Croatia	1	Romania & Germany	1
Greece	2	Finland	1	USA & EU	1
Italy	2	Germany	1		
Taiwan	2	Israel	1		
United Kingdom	2	Latvia	1		

#### 3. Results

#### 3.1. Search results

3436 studies were identified from the literature search, representing 2891 studies following removal of duplicates. Title and abstract based screening resulted in 2679 articles being removed, which left 212 for full text assessment. Full text evaluation resulted in 35 articles being shortlisted for the review (Fig. 1).

#### 3.2. Study characteristics

From the 35 articles identified, 29 were full text articles (83%) and 6 (17%) were only in abstract form, typically from conference presentations (Table 1).

The study designs noted within the review were:

The distribution of studies over time is described in Fig. 2:

(11%) studies were based on international datasets, 12studies (34%) were conducted based on national data, 9studies (26%) used regional data, 10 (29%) were single-centre studies. The distribution of study geographies is shown in Table 2:

#### 3.3. Risk factor identification

The majority of studies analysed (24studies, 69%) identified one or more statistically significant risk factors for mortality, following discharge from hospital with a co-morbid diagnosis of diabetes. There were 11 studies (31%), which identified no statistical significant risk factors. The distribution of risk factors is demonstrated in more detail in Table 3.

The follow up period, during which mortality was looked for in the studies, was highly variable. The most common follow up period was



### Studies over time

Fig. 2. Studies over time.

#### T. Mukherjee et al. / Journal of Diabetes and Its Complications xxx (xxxx) xxx

٠	۲	

Table 3 Study characteristics.

Ref	Year	Data collection	Sample size	Sub-population	Significant risk factors	No. of significant risk factors	Follow up period (years)
12	2017	Regional	22,473	Post Intensive Care Unit (ICU)	Hospital, age, sex, ethnicity, APACHE score, co-morbidity	6	5.1
13	2016	National	1613	Post Myocardial Infarction (MI)	Admission creatinine, employment, age, Haemoglobin (Hb), Left Ventricular Systolic Dysfunction (LVSD), co-morbidity, activity, in hospital revascularisation, BMI, insulin, fasting blood glucose, angina frequency	12	5
14	2017	Regional	59,412	All diabetes	Not specific	0	Until death
15	2018	Single	312	Age over 60	Gait speed, calf circumference (BMI)	2	NA
16	2015	Single	4607	All diabetes	Age, Gender, Cardiovascular diseases and infectious diseases (co-morbidity)	4	337 davs
17	2014	National	1082	Heart failure	Age, co-morbidity, sodium (biochemistry), anaemia (haematology), medication. BML NHYA (severity scoring)	7	1
18	2015	National	2904	Chronic Kidney Disease (CKD) and acute MI admission	0	0	1
19	2015	National	4054	Admission for acute MI	Statins prior to acute ML number of medications	2	3
20	2018	Single	207	Diabetic Ketoacidosis	Age duration of diabetes number of hospitalisations	3	5
	2010	Single	207	(DKA) diagnosed	rige, duration of diabetes, number of nospitalisations	5	5
21	2016	Single	409	Admitted with pneumonia	Hospitalization for pneumonia (admission diagnosis) Age, haemodialysis (procedure) Charlson co-morbidity index (score) renal insufficiency, pleural effusion, malnutrition (co-morbidity) pH < 7 35 (hiochemistry)	8	1
22	2017	Single	761	Admitted with poor glucose control	Estimated Glomerular Filtration Rate (eGFR), Albuminuria (biochemistry)	2	6.6
23	2016	International	5005	Patients admitted with acute decompensated heart failure with diabetes	BMI (underweight, severely obese)	2	1
24	2018	Single	304	All diabetes	0	0	1
25	2019	Regional	104,525	Patients hospitalised and dispensed prescription for insulin and/or OHA within 8	new insulin use (medication)	1	30 days
26		<i>a</i> : 1		days of discharge. Age $> 66$ years			
20	2018	Single	130	Type 2 Diabetes Mellitus (T2DM)	0	0	30 days
27	2017	Single	304	T2DM patients with first ever noncardioemobolic acute ischemic stroke	Age, Stroke severity (NIHSS scale), clopidogrel compared to aspirin (medication) co-morbidity	4	10
28	2016	National	386	DKA admitted to Intensive Treatment Unit (ITU)	Age, APACHEII score, mechanical ventilation, number of organs supported, DKA severity, creatinine, bilirubin, pCO2 (biochemistry), lowest Glasgow Coma Score (GCS)	9	5
29	2016	Regional	214,991	All diabetes	Age, sex, Charlson index	3	2
30	2018	National	17,186	Diabetes and heart failure	0	0	NA
31	2016	National	1743	Diabetes and Acute Coronary Syndrome (ACS)	0	0	6 months
32	2019	National	843,978	All diabetes	0	0	6 months
33	2017	National	71,640	Diabetes and cancer	0	0	3
34	2017	Regional	28,353	All diabetes	Median glucose during admission & glucose variability	2	6
35	2015	International	221	T2DM admitted with ACS	0	0	1
36	2014	International	1998	Patients hospitalised with worsening heart	0	0	9.9
37	2017	Regional	218	tailure and an ejection fraction below 40% Haematocrit, EF, ACEi. Red blood cell distribution	0	0	months 1
38	2017	Single	202	All diabetes	hba1c, insulin resistance	2	2.5
39	2020	International	974	ACS	Fibrinolysis	1	1
40	2019	Single	306	All diabetes	Sarcopenia	1	2
41	2019	Regional	10.542	All diabetes	Heat wave intensity	1	NA
42	2019	National	13,113	Heart failure	Diabetes and heart failure	1	1
43	2019	National	41,776	Heart failure	0	0	1
44	2019	Regional	NA	All diabetes	Pharmacy follow up	1	90 days
45	2019	National	1221	Acute MI	Insulin prescription at discharge	1	5
46	2019	Regional	100,000	T2DM over 40 years	Lower limb amputation, sex	2	10

12 months in 8 studies (23%). The shortest follow up period was 1 month and the longest follow up period was 10 years.

The extracted studies varied according to whether they considered risk in all patients with diabetes (6 studies, 17%) or a specific sub population. Those sub populations were defined either by the type of diabetes, or the characteristics relevant to the inpatient stay, and are demonstrated in more detail in Table 3.

In total, there were 48 distinct risk factors identified. These can be grouped into risk factor categories, alongside grouping according to whether they were identified for all patients with diabetes. The results of this grouping is shown in Table 4, which represents a complete list of all statistically significant risk factors identified within the published research literature, alongside the number (and references) of studies, which identified these risk factors as significant.

#### 3.4. Study quality

The sample size of extracted studies varied between 130 participants and 843,978 participants. The mean average number of participants per study was 44,484, with a median of 1743 participants.

#### T. Mukherjee et al. / Journal of Diabetes and Its Complications xxx (xxxx) xxx

### Table 4

Risk factorNumber of studies & RefRisk FactorNo.& RefDemographic Age712.13.172.02.12.4.27.28 GenderAge Gender216.29Age112.66Gender216.29Socioeconomic status113Lifestyle Leisure time activity113LifestyleLifestyleComorbidityLeisure time activity113ComorbidityPatient medical factorsComorbidity612.13.172.52.7.42 0ComorbidityComorbidity612.13.172.52.7.42 10Comorbidity216.29.40Malnutrition121 120Comorbidity216.29.40Duration of diabetes120 120Comorbidity216.29.40Kas Severity147 170Comorbidity216.29.40Jumation of diabetes120 120Comorbidity216.29.40Jumation of diabetes120 120Comorbidity216.29.40Jumation of diabetes120 120Comorbidity216.29.40Jumation of diabetes120 120Comorbidity216.29.40Jumation of diabetes120 120Comorbidity216.29.40Jumation of diabetes120 120Comorbidity216.29.40Jumation of diabetes120 120Comorbidity216.29.40Inpatient stay factors131Procedure216.29.40No. of hospitalisations120 120Procedure131.172.20No. of medications related120 120Procedure141Beta blocker177 170 170Pharm	Risk factors for specific dia subpopulations	betes	Risk factors in general diabetes populations		
Demographic Age Gender71243.17.20.21.24.27.28 GenderAge Gender21-23-32 21-23-32 21-23-32 21-23-32 21-23-32 21-23Socioeconomic status Employment status13 <td>Risk factor</td> <td>Number of studies &amp; Ref</td> <td>Risk Factor</td> <td>No.&amp; Ref</td>	Risk factor	Number of studies & Ref	Risk Factor	No.& Ref	
Age712.317.20.21.24.27.28Age216.29Gender112.46Gender216.29Race112Gender216.29Socioeconomic status113LifestyleLifestyle113LifestyleLeisure time activity113LifestyleExternal factorsweather conditions141Patient medical factorsCo-morbidity121Duration of diabetes120Severity score412.17.27.28DKA Severity147Co-morbidity121Duration of diabetes120Severity score115Call circumference115Call speed115Call factors113Severity score113Inpain frequency113Severity144Clasgow coma score128SupportedSeverityNo. of hospitalisations120Severity144Clasgow coma score128SupportedSeverityNo. of hospitalisations120Severity144Clasgow coma score127Severity144Statins prior to AMI119Soitanspei144No. of medication sat119Soitanspei144Clasgow comeation sat121Severity144Clasgow comeation sat121Severity144Statins prior to AMI119Severity144Statins prior to AMI119Severity144Statins prior to AMI121Severity145Clopidogrel127 </td <td>Demographic</td> <td></td> <td></td> <td></td>	Demographic				
Cender112.Cender210.33Race112113114Socioeconomic status113115Lifestyle113114Lifestyle113114External factorsVeather conditions141Patient medical factorsCo-morbidity612.13.17.25.27.42Co-morbidity216.29.40Malnutrition121Co-morbidity612.13.17.23.27.28Co-morbidity216.29.40Malnutrition147Co-morbidity612.13.17.23.27.28Co-morbidity216.29.40Severity score412.17.27.28Co-morbidity216.29.40DKA Severity147Co-morbidity216.29.40Body mass index31.31.72.3Co-morbidity216.29.40Calf circumference115Calf circumference115Calf circumference113Co-morbidity144Inpatient stay factors124Casgow coma score128No of hospitalisations120Veather conditions144Calagow coma score128Veather condition up144No of medications119No. Griedications120No. of medications119No. Griedications131No. Griedications144Sodium seve132.8Hba1c138Fasting glucose133Sodium level144Fasting glucose136132144Fasting glucose137Co-morbidity144Fasting glucose138136144Fasting	Age	7 <sup>12,13,17,20,21,24,27,28</sup>	Age	2 <sup>16,29</sup>	
Race112Socioeconomic status Employment status113Lifestyle Leisure time activity113External factorsweather conditions141Patient medical factors Co-morbidity6[213,17,2527,42] 0Co-morbidity215.29,40Mainutrition121 0Duration of diabetes120 0215.29,40Severity score412.1727,28Auser time activity141Duration of diabetes120 177,23Co-morbidity215.29,40KA Severity147 170Body mass index131.172.3Cait speed115 Calf circumference115 	Gender	112,46	Gender	216,29	
Soloideconomic status Employment status13Lifesiye leisure time activity13External factorsweather conditions14External factors011Co-morbidity612.13.17.25.27.42 AdalnutritionCo-morbidity216.39.40Mainutrition12011Duration of diabetes120 Severity score121.77.2814Severity score121.77.281414Body mass index13.17.231414Admiss peed151514Admiss datas121.72.81414Admiss of datas121.72.81414Admission diagnosis1211414Caspow coma score1281414Caspow coma score1281414Number of organs1201414Number of organs1201414Number of organs1201414Number of organs1201414Number of organs1201414Number of organs13.281414Number of ordion related1717Statis prior to AM1314Number of ordion relation13.2814Admission creatine13.2814Admission creatine13.2814Fading fucce17Photemut 2201314Odum level1414Admission haemogloin13Admission haemogloin <td>Race</td> <td>112</td> <td></td> <td></td>	Race	112			
Lifestyle Leisure time activity $1^{13}$ External factorsNeather conditions $1^{41}$ Patient medical factorsCo-morbidity $1^{213,17,25,27,42}$ Neather conditions $1^{21}$ Duration of diabetes $1^{20}$ Severity score $4^{12,17,27,28}$ Neather conditions $2^{16,29,40}$ Body mass index $3^{13,17,23}$ Gait speed $1^{5}$ HermitianHermitianHermitianBody mass index $3^{13,17,23}$ Gait speed $1^{5}$ HermitianHermitianHermitianCalf circumference $1^{50}$ HermitianHermitianHermitianHermitianHermitianInpatient stay factors $1^{21}$ HermitianHermitianHermitianHermitianMechanical ventilation $1^{28}$ HermitianHermitianHermitianHermitianNo. of hospitalisations $1^{20}$ HermitianHermitianHermitianNo. of hospitalisations $1^{20}$ HermitianHermitianHermitianSubcker $1^{70}$ Hermitian $1^{24}$ HermitianHermitianAdmission creating $1^{53}$ HermitianHermitianHermitianHermitianBeta blocker $1^{70}$ Hermitian $1^{30}$ HermitianHermitianHermitianAdmission creating $1^{53}$ HermitianHermitianHermitianHermitianAdmission creating $1^{23}$ HermitianHermitianHermitianHermitianAdmission creating $1^{23}$ $1^{24}$	Socioeconomic status Employment status	1 <sup>13</sup>			
External factorsWeather conditions141Patient medical factors61Co-morbidity612.13.72.52.74.2Co-morbidity21-5.3.4Maluurition1212Duration of diabetes12012Severity score13.72.314Body mass index13.72.314Calit speed1514Calit speed1514Calit speed1314Inpatient stay factors13Procedure132.146Admission diagnosi12Calogow coma score12Calogow coma score12No flospitalisations12No flospitalisations12No flospitalisations12No flospitalisations12No flospital admitted12No flospital admitted13No flospital admitted14Paratory results14Admission creation13No flospital admitted13No flospital admitted13No f	Lifestyle Leisure time activity	1 <sup>13</sup>			
Patient medical factorsCo-morbidity $6^{12,13,17,25,27,42}$ Co-morbidity $2^{16,29,40}$ Malnutrition12Duration of diabetes20Severity score $4^{12,17,27,28}$ DKA Severity14Body mass index $3^{13,17,23}$ Gait speed15Calf circumference15Angina frequency13Inpatient stay factors13Procedure $2^{13,21,46}$ Admission diagnosis24Clasgow coma score28(GCS)12Mechanical ventilation28supported12No. of hospitalisations10Uhetic hospital admitted12to12No. of nospitalisations10Medication related12Beta blocker17Attins prior to AMI19discharge13Insuin use25,45Clopidogrel21Phermacy follow up144Admission reatinine213,28Admission reatinine213,28Phermacy follow up13Admission reatinine213,28Phermacy follow up13Outon fulces12Cologital status (not int time status stat	External factors		Weather conditions	1 <sup>41</sup>	
Co-morbidity 6 12.13.17.23.27.42 Co-morbidity 6 12.13.17.23.27.42 Duration of diabetes 120 Severity score 4 12.17.27.28 DKA Severity 147 Body mass index 313.17.23 Cait speed 15 Caif circumference 115 Angina frequency 113 Inpatient stay factors Procedure 213.21.46 Admission diagnosis 121 Length of stay 124 Clasgow coma score 128 (GCS) Mechanical ventilation 128 Number of organs 128 supported No. of hospitalisations 120 Which hospital admitted 112 to Medication related Beta blocker 117 ACEi/ARB blocker 117 Statins prior to AMI 119 No. of medications at 119 discharge Insulin use 125.45 Clopidogrel 127 Laboratory results Admission reatinine 213.28 Fasting glucose 113 Sodium level 117 Beta blockr 117 Admission reatinine 213.28 Fasting glucose 113 Sodium level 117 Ph below 7.35 121 eGFR 122 Admission haemoglobin 113 Anaemia 127 Fibrinolysis 139 Clycaemic Status (not incluting Hba1c above) Glycaemic Status (not incluting Hba1c above) Fibrinolysis 139	Patient medical factors				
Le manufaction of diabetes 120 Duration of diabetes 120 Severity score 412.1727.28 DKA Severity 147 Body mass index 313.1723 Gait speed 115 Calf circumference 115 Angina frequency 113 Inpatient stay factors Procedure 21321.46 Admission diagnosis 121 Length of stay 124 Calsgow coma score 128 (CCS) Mechanical ventilation 128 Number of organs 128 supported No. of hospitalisations 120 Which hospital admitted 112 to Medication related Beta blocker 117 ACEi/ARB blocker 117 No. of medications at 119 discharge Insulin use 125.45 Clopidogrel 127 Laboratory results Admission creatine 213.28 Hba1c 138 Fasting glucose 113 Sodium level 117 pH below 7.35 121 eGFR 122 Albuminura 122 Bilirubin 128 Proce 113 Sodium level 117 pH below 7.35 121 eGFR 122 Albuminura 122 Bilirubin 128 Proce 133 Proce 13	Co-morbidity	6 <sup>12,13,17,25,27,42</sup>	Co-morbidity	$2^{16,29,40}$	
Duration of diabetes 120 Severity score 412.17.27.28 DKA Severity 1 14 DKA Severity 115 Calf circumference 115 Angina frequency 113 Inpatient stay factors Procedure 213.21.46 Admission diagnosis 121 Length of stay 124 Clasgow coma score 128 (GCS) Mechanical ventilation 128 Number of organs 120 Which hospital admitted 112 to Medication related Beta blocker 117 Statins prior to AMI 119 No. of medications a 19 discharge Insulin use 125.45 Clopidogrel 127 Laboratory results Admission creatinine 213.28 Hba1c 1 <sup>38</sup> Fasting glucose 113 Sodium level 117 pH below 7.35 1 <sup>21</sup> eGFR 122 Albuminura 122 Bilirubin 1 <sup>28</sup> PCO2 (on blood gas) 1 <sup>28</sup> Admission haemoglobin 113 Anaemia 127 Fibrinolysis 1 <sup>39</sup> Clycaemic Status (not inclusting Hba1c above) Clycaemic Status (not inclusting Hba1c above)	Malnutrition	1 <sup>21</sup>	co morbialty	2	
Severity score $4^{12,17,27,28}$ DKA Severity $1^{47}$ Body mass index $3^{13,17,23}$ Gait speed $1^{15}$ Calf circumference $1^{15}$ Angina frequency $1^{3}$ Inpatient stay factors Procedure $2^{13,21,46}$ Admission diagnosis $1^{21}$ Length of stay $1^{24}$ Glasgow coma score $1^{28}$ Number of organs $1^{28}$ Number of organs $1^{28}$ Number of organs $1^{28}$ Number of organs $1^{20}$ Which hospitaliations $1^{20}$ Which hospitaliations $1^{20}$ Which hospitaliations $1^{20}$ Which hospitaliations $1^{20}$ Which bospitaliations $1^{20}$ Mathematical vertilation $1^{17}$ Statins prior to AMI $1^{19}$ No. of medications at $1^{17}$ Statins prior to AMI $1^{19}$ No. of medications at $1^{27}$ Laboratory results Admission creatinine $2^{13,28}$ Fasting glucose $1^{13}$ Sodium level $1^{17}$ pH below 7.35 $1^{21}$ eGFR $1^{22}$ Albuminura $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{28}$ Admission haemoglobin $1^{13}$ Anaemia $1^{27}$ Fibrinolysis $1^{39}$ Glycaemic Status (not inclusting Hba1c above) Glycaemic Status (not inclusting Hba1c above) Anaemia $1^{27}$ Fibrinolysis $1^{39}$	Duration of diabetes	1 <sup>20</sup>			
DKA Severity147Body mass index $3^{13,17,23}$ Gait speed $1^{15}$ Calf circumference $1^{15}$ Angina frequency $1^{13}$ Inpatient stay factors $2^{13,21,46}$ Admission diagnosis $2^{11}$ Length of stay $2^{24}$ Calsgow coma score $2^{28}$ (GCS) $2^{12}$ Mechanical ventilation $2^{28}$ Number of organs $2^{20}$ No. of hospitalisations $2^{0}$ Which hospital admitted $1^{12}$ to $1^{44}$ ACEi/ARB blocker $1^{17}$ No. of medications at $1^{19}$ No. of medications at $1^{19}$ No. of medications at $1^{19}$ No. of medications at $1^{12}$ discharge $1^{13}$ Insulin use $2^{15,265}$ Clopidogrel $1^{27}$ Hablox 7.35 $2^{11}$ PHolow 7.35 $2^{11}$ eGFR $2^{22}$ Albuminura $2^{22}$ Bilirubin $2^{28}$ PCO2 (on blood gas) $2^{28}$ PCO2 (on blood gas) $2^{28}$ Admission haemoglobin $1^{3}$ Anaemia $2^{77}$ Fibrinolysis $3^{39}$ Clycaemic Status (not incluting Hbalt c above) $1^{34}$ Mean capillary blood $1^{34}$ Man capillary blood $1^{34}$ Anaemia $2^{77}$ Fibrinolysis $3^{39}$ Clycaemic Status (not inclution trace	Severity score	4 <sup>12,17,27,28</sup>			
Body mass index $3^{13,17,23}$ Gait speed $1^{15}$ Calf circumference $1^{15}$ Calf circumference $1^{15}$ Angina frequency $1^{13}$ Inpatient stay factors $2^{13,21,46}$ Admission diagnosis $2^{11}$ Length of stay $2^{14}$ Calfacy coma score $2^{18}$ (GCS)Medication diagnosis $1^{21}$ Length of stay $1^{24}$ Clasgow coma score $1^{28}$ supported $1^{20}$ Number of organs $1^{20}$ Vhich hospital admitted $1^{12}$ toMedication related $1^{12}$ to $1^{44}$ Beta blocker $1^{17}$ dischargePharmacy follow up $1^{44}$ Insulin use $1^{25,45}$ Clopidogrel $1^{27}$ $1^{38}$ Isodiations $1^{10}$ discharge $1^{17}$ PH below 7.35 $1^{21}$ eGFR $1^{22}$ Albuminura $1^{22}$ eGFR $1^{23}$ Admission haemoglobin $1^{38}$ PCO2 (on blood gas) $1^{28}$ PCO2 (on blood gas) $1^{29}$ PCO2 (on blood gas) $1^{20}$ PCO2 (on blood gas)	DKA Severity	147			
Gait speed115Calf circumference115Angina frequency113Inpatient stay factors $2^{13,21,46}$ Admission diagnosis121Length of stay124Glasgow coma score128(GCS)(GCS)Mechanical ventilation128Number of organs120Which hospital isations120Which hospital isations120Which hospital isations120Medication related112to144ACEi/ARB blocker117ACEi/ARB blocker119No. of medications at119No. of medications at127Laboratory resultsHba1cAdmission creatinine213,28Fasting glucose113Sodium level177PH below 7,35121eCFR122Albuminura122Blirubin128PCO2 (on blood gas)128PCO2 (on blood gas)128PCO2 (on blood gas)138Anaemia127Fibrinolysis139Glycaemic Status (not incluming Hba1c above)Glycaemic variabilityGlycaemic Status (not incluming Hba1c above)138Mean capillary blood138Admission haemoglobin138Anaemia129<	Body mass index	3 <sup>13,17,23</sup>			
Calf circumference115Angina frequency113Inpatient stay factors132Procedure21321.46Admission diagnosis121Length of stay124Glasgow coma score128(GCS)120Mechanical ventilation128Number of organs120Number of organs120Which hospital admitted112to112to113Medication related114Beta blocker117Statins prior to AMI119No. of medications at119discharge137Insulin use125.45Clopidogrel127Laboratory results131Admission creatinine213.28Fasting glucose113Sodium level117PH below 7.35121eGFR122Albuminura128PCO2 (on blod gas)128Admission haemoglobin113Anaemia127Fibrinolysis139Glycaemic Status (not incl//ing Hba1c above)Glycaemic variabilityGlycaemic Status (not incl//ing Hba1c above)138Mean capillary blood138Mean capillary blood138Admission haemoglobin138Anaemia120Billrubin139Glycaemic Status (not incl//ing Hba1c above)138Mean capillary blood138Mean capillary blood138Mean capillary blood138	Gait speed	1 <sup>15</sup>			
Angina frequency113Inpatient stay factors213.21.46Procedure213.21.46Admission diagnosis121Length of stay124Glasgow coma score128(GCS)"Mechanical ventilationNumber of organs126supported122No. of hospitalisations120Which hospital admitted112to124AcEi/ARB blocker117Statins prior to AMI119No. of medications at119discharge127Laboratory results125.455Clopidogrel127Laboratory results13Admission creatinine213.28Phalow 7.35121eGFR122Albuminura122Bilrubin128PCO2 (on blod gas)128PCO2 (on blod gas)128PCO2 (on blod gas)13Anaemia127Fibrinolysis139Glycaemic Status (not incluting Hba1c above)Glycaemic variabilityInsulin resistance138Admission haemoglobin138Anaemia127Fibrinolysis139Glycaemic Status (not incluting Hba1c above)138Mean capillary blood138glucose138Resistance138Admission haemoglobin138Anaemia127Elbrinolysis139Glycaemic Status (not incluting Hba1c above)138Admission haemoglobin138	Calf circumference	1 <sup>15</sup>			
Inpatient stay factors13.21.46Admission diagnosis121Length of stay124Glasgow coma score128(GCS)	Angina frequency	1 <sup>13</sup>			
Procedure $2^{13,21,46}$ Admission diagnosis $1^{21}$ Length of stay $1^{24}$ Glasgow coma score $1^{28}$ Number of organs $1^{28}$ Number of organs $1^{20}$ Which hospitalisations $2^{20}$ Which hospitalisations $1^{20}$ Which hospitalisations $1^{20}$ Which hospitalisations $1^{20}$ Medication relatedBeta blocker $1^{17}$ Pharmacy follow up $1^{44}$ ACE:/ARB blocker $1^{17}$ Statins prior to AMI $1^{19}$ No. of medications at $1^{19}$ discharge $1^{27}$ Laboratory resultsAdmission creatinine $2^{13,28}$ Fasting glucose $1^{17}$ pH below 7.35 $2^{21}$ eGFR $1^{22}$ Albuminura $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{28}$ PCO2 (on blood gas) $1^{28}$ Admission haemoglobin $1^{13}$ Anaemia $1^{27}$ Fibrinolysis $1^{39}$ Glycaemic Status (not including Hba1c above) $Gycaemic variability$ $flaeglucoseInsulin resistance1^{36}$	Inpatient stay factors				
Admission diagnosis $1^{21}$ Length of stay $1^{24}$ Glasgow coma score $1^{28}$ Mechanical ventilation $1^{28}$ Number of organs $1^{28}$ Number of organs $1^{20}$ Which hospital admitted $1^{12}$ to $1^{44}$ Medication related Beta blocker $1^{17}$ ACEi/ARB blockerPharmacy follow up $1^{44}$ ACEi/ARB blocker $1^{17}$ Statins prior to AMI $1^{19}$ discharge Insulin use $1^{25,455}$ Clopidogrel $1^{27}$ Laboratory results Admission creatinine $2^{13,28}$ $1^{17}$ pH below 7.35Hba1c $1^{38}$ Fasting glucoseSodium level $1^{17}$ pH below 7.35 $1^{21}$ $2^{22}$ Albuminura $1^{22}$ $2^{23}$ Admission haemoglobin $1^{33}$ AnaemiaGlycaemic Status (not incluing Hba1c above) $Glycaemic variability$ $Mean capillary blood1^{38}glucoseInsulin resistance1^{38}1^{38}$	Procedure	2 <sup>13,21,46</sup>			
Length of stay124Glasgow coma score128(GCS)128Mechanical ventilation128supported120No. of hospitalisations120Which hospital admitted112to112to113Medication related119Beta blocker117Statins prior to AMI119No. of medications at119discharge127Insulin use125,455Clopidogrel127Laboratory results113Admission creatinine213,28Admission creatinine213,28PhaltHbaltc138Sodium level117pH below 7.35121eGFR122Albuminura122Bilirubin128PCO2 (on blood gas)128Admission haemoglobin113Anaemia127Glycaemic Status (not incluting Hbaltc above)Glycaemic variabilityGlycaemic status (not incluting Hbaltc above)138glucose139Glycaemic variability134Mean capillary blood138glucose138Glycaemic variability134Maen capillary blood138glucose138Glycaemic variability134Maen capillary blood138Maen capillary blood138Maenia138Maenia138Maenia138Maenia138Maenia <td>Admission diagnosis</td> <td>1<sup>21</sup></td> <td></td> <td></td>	Admission diagnosis	1 <sup>21</sup>			
Glasgow coma score (GCS) $1^{28}$ Mechanical ventilation $1^{28}$ Number of organs $1^{28}$ supported $1^{28}$ No. of hospitalisations $1^{20}$ Which hospital admitted $1^{12}$ to $1^{21}$ Medication related $1^{17}$ Beta blocker $1^{17}$ Statins prior to AMI $1^{19}$ discharge $1^{17}$ Insulin use $1^{25,45}$ Clopidogrel $1^{27}$ Laboratory results $1^{21}$ Admission creatinine $2^{13,28}$ Hba1c $1^{38}$ Fasting glucose $1^{13}$ Sodium level $1^{17}$ PH below 7.35 $1^{21}$ eGFR $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{28}$ PCO2 (on blood gas) $1^{30}$ Glycaemic Status (not incl/Ling Hba1c above)Glycaemic status (not incl/Ling Hba1c above)Glycaemic variability $1^{34}$ Mean capillary blood $1^{38}$ glucose $1^{38}$ insulin resistance $1^{38}$	Length of stay	124			
Mechanical ventilation $1^{28}$ Number of organs $1^{28}$ supported $1^{20}$ No. of hospitalisations $1^{20}$ Which hospital admitted $1^{12}$ to $1^{21}$ to $1^{22}$ Medication related $1^{22}$ Beta blocker $1^{17}$ Pharmacy follow up $1^{44}$ ACEi/ARB blocker $1^{17}$ Statins prior to AMI $1^{19}$ discharge $1^{27}$ Insulin use $1^{25,45}$ Clopidogrel $1^{27}$ Laboratory results $1^{38}$ Admission creatinine $2^{13,28}$ Phelow 7.35 $1^{21}$ eGFR $1^{22}$ Bilirubin $1^{22}$ Bilirubin $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{28}$ PCO2 (on blood gas) $1^{28}$ PCO2 (on blood gas) $1^{29}$ Glycaemic Status (not incluting Hba1c above) $Glycaemic variability$ Glycaemic Status (not incluting Hba1c above) $Glycaemic variability$ $1^{38}$ $glucose$ $1^{38}$ $glucose$ $1^{38}$ $glucose$ $1^{38}$	Glasgow coma score (GCS)	1 <sup>28</sup>			
Number of organs supported $1^{28}$ Number of organs supported $1^{20}$ No. of hospitalisations $1^{20}$ Which hospital admitted $1^{12}$ to $1^{12}$ Medication relatedBeta blocker $1^{17}$ Pharmacy follow up $1^{44}$ ACEi/ARB blocker $1^{17}$ Statins prior to AMI $1^{19}$ No. of medications at discharge $1^{19}$ Insulin use $1^{25,45}$ Clopidogrel $1^{27}$ Laboratory resultsAdmission creatinine $2^{13,28}$ Hba1c $1^{38}$ Fasting glucose $1^{17}$ pH below 7.35 $1^{21}$ eGFR $1^{22}$ Albuminura $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{28}$ PCO2 (on blood gas) $1^{28}$ PCO2 (on blood gas) $1^{29}$ Glycaemic Status (not inclus Hba1c above) $Glycaemic variability$ Glycaemic Status (not inclus Hba1c above) $Glycaemic variability$ $1^{38}$ $1^{38}$ glucose Insulin resistance $1^{38}$	Mechanical ventilation	1 <sup>28</sup>			
No. of hospitalisations 1 <sup>20</sup> Which hospital admitted 1 <sup>12</sup> to Medication related Beta blocker 1 <sup>17</sup> Statins prior to AMI 1 <sup>19</sup> No. of medications at 1 <sup>19</sup> discharge Insulin use 1 <sup>25,45</sup> Clopidogrel 1 <sup>27</sup> Laboratory results Admission creatinine 2 <sup>13,28</sup> Fasting glucose 1 <sup>13</sup> Sodium level 1 <sup>17</sup> pH below 7,35 1 <sup>21</sup> eGFR 1 <sup>22</sup> Albuminura 1 <sup>22</sup> Bilirubin 1 <sup>28</sup> PCO2 (on blood gas) 1 <sup>28</sup> PCO2 (on blood gas) 1 <sup>28</sup> Admission haemoglobin 1 <sup>13</sup> Anaemia 1 <sup>27</sup> Fibrinolysis 1 <sup>39</sup> Glycaemic Status (not incluting Hba1c above) Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	Number of organs	128			
No. of nospital admitted 1 <sup>12</sup> to Medication related Beta blocker 1 <sup>17</sup> ACEi/ARB blocker 1 <sup>17</sup> Statins prior to AMI 1 <sup>19</sup> No. of medications at 1 <sup>19</sup> discharge Insulin use 1 <sup>25,45</sup> Clopidogrel 1 <sup>27</sup> Laboratory results Admission creatinine 2 <sup>13,28</sup> Fasting glucose 1 <sup>13</sup> Sodium level 1 <sup>17</sup> pH below 7.35 1 <sup>21</sup> eGFR 1 <sup>22</sup> Albuminura 1 <sup>22</sup> Bilirubin 1 <sup>28</sup> PCO2 (on blood gas) 1 <sup>28</sup> PCO2 (on blood gas) 1 <sup>28</sup> Admission haemoglobin 1 <sup>13</sup> Anaemia 1 <sup>27</sup> Fibrinolysis 1 <sup>39</sup> Glycaemic Status (not incluting Hba1c above) Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	supported	120			
Which hospital admitted1toMedication relatedPharmacy follow up $1^{44}$ Beta blocker $1^{17}$ Pharmacy follow up $1^{44}$ ACEi/ARB blocker $1^{17}$ Pharmacy follow up $1^{44}$ ACEi/ARB blocker $1^{19}$ No. of medications at $1^{19}$ No. of medications at $1^{19}$ $1^{19}$ $1^{19}$ No. of medications at $1^{19}$ $1^{19}$ $1^{19}$ Isotarge $1^{27}$ $1^{27}$ $1^{27}$ Laboratory resultsHba1c $1^{38}$ Admission creatinine $2^{13,28}$ $1^{21}$ Sodium level $1^{17}$ $1^{21}$ pH below 7.35 $1^{21}$ eGFR $1^{22}$ Albuminura $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{29}$ Glycaemic Status (not incluting Hba1c above) $Glycaemic variability$ $1^{34}$ Mean capillary blood $1^{38}$ glucose $1^{38}$ nsulin resistance $1^{38}$	No. of Hospitalisations	112			
Medication relatedPharmacy follow up $1^{44}$ Beta blocker117Pharmacy follow up $1^{44}$ ACEI/ARB blocker11719Statins prior to AMI1919No. of medications at11919discharge125,45100Clopidogrel127138Laboratory results13Admission creatinine213,28Hba1c138Fasting glucose113Sodium level171pH below 7.35121eGFR122Bilirubin128PCO2 (on blood gas)128PCO2 (on blood gas)13Anaemia127Fibrinolysis139Glycaemic Status (not inct lurg Hba1c above)Glycaemic variability $1^{34}$ Mean capillary blood138glucose138Sodium level139134Anaemia127134Anaemia127Fibrinolysis139134Minesistance138Sodium level138Sodium level138Admission haemoglobin134Anaemia127Fibrinolysis139Sodium level138Sodium level138Sodium level138Admission haemoglobin134Anaemia139Sodium level138Sodium level138Sodium level138Sodium level138Sodium level138So	to	I			
Beta blocker117Pharmacy follow up $1^{44}$ ACEi/ARB blocker117Statins prior to AMI119No. of medications at119discharge125,45Insulin use125,45Clopidogrel127Laboratory results13Admission creatinine213,28Hba1c138Fasting glucose113Sodium level171pH below 7.35121eGFR122Albuminura122Bilirubin128PCO2 (on blood gas)128Anaemia127Fibrinolysis139Glycaemic Status (not incluting Hba1c above)Glycaemic variabilityIf all use in consultation of the status (not incluting Hba1c above)138glucose <td>Medication related</td> <td></td> <td></td> <td></td>	Medication related				
ACE1/ARB blocker $1^{17}$ Statins prior to AMI $1^{19}$ No. of medications at $1^{19}$ discharge $1^{25,45}$ Insulin use $1^{27}$ Laboratory results $1^{27}$ Admission creatinine $2^{13,28}$ Hba1cAdmission creatinine $1^{13}$ Sodium level $1^{17}$ pH below 7.35 $1^{21}$ eGFR $1^{22}$ Albuminura $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{28}$ PCO2 (on blood gas) $1^{36}$ Anaemia $1^{27}$ Fibrinolysis $1^{39}$ Glycaemic Status (not inclus Hba1c above)Glycaemic variability $1^{38}$ $1^{38}$ glucose $1^{38}$ glucose $1^{38}$ glucose $1^{38}$ glucose $1^{38}$ glucose $1^{38}$ glucose $1^{38}$	Beta blocker	117	Pharmacy follow up	144	
Statins prior to AMI $1^{19}$ No. of medications at $1^{19}$ discharge $1^{19}$ Insulin use $1^{25,45}$ Clopidogrel $1^{27}$ Laboratory results $1^{27}$ Admission creatinine $2^{13,28}$ Biglicose $1^{13}$ Sodium level $1^{17}$ Ph below 7.35 $2^{12}$ Albuminura $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{28}$ PCO2 (on blood gas) $1^{28}$ Anaemia $1^{27}$ Fibrinolysis $1^{39}$ Glycaemic Status (not incluting Hba1c above) $Glycaemic variability$ Image: Constraint of the status of the status (not incluting Hba1c above) $1^{38}$ glucose $1^{38}$ Image: Constraint of the status o	ACEi/ARB blocker	117			
No. or medications at discharge122Insulin use125,45Clopidogrel127Laboratory results13Admission creatinine213,28Hba1c138Fasting glucose113Sodium level117pH below 7.35121eGFR122Albuminura122Bilirubin128PCO2 (on blod gas)133Anaemia17Fibrinolysis139Glycaemic Status (not in: Um Hba1c above)Glycaemic variability134 Mean capillary blod138139Glycose138Interpret and the second	Statins prior to AMI	119			
Insulin use       125,45         Clopidogrel       127         Laboratory results       127         Admission creatinine       213,28         Hba1c       138         Fasting glucose       113         Sodium level       117         pH below 7.35       121         eGFR       122         Albuminura       122         Bilirubin       128         PCO2 (on blood gas)       128         Admission haemoglobin       113         Anaemia       127         Fibrinolysis       139         Glycaemic Status (not incture Hba1c above)       Glycaemic variability       134         Mean capillary blood       138         glucose       138         Insulin resistance       138	No. of medications at	1			
Instant lac1Clopidogrel127Laboratory results13Admission creatinine213.28Hba1c138Fasting glucose11Sodium level117pH below 7.35121eGFR122Albuminura122Bilirubin28Admission haemoglobin113Anaemia127Fibrinolysis139Glycaemic Status (not inclus Hba1c above)Glycaemic variability134Mean capillary blood138glucose138Insulin resistance138	Insulin use	125,45			
Laboratory results Admission creatinine 2 <sup>13,28</sup> Hba1c 1 <sup>38</sup> Fasting glucose 1 <sup>13</sup> Sodium level 1 <sup>17</sup> pH below 7.35 1 <sup>21</sup> eGFR 1 <sup>22</sup> Albuminura 1 <sup>22</sup> Bilirubin 2 <sup>28</sup> PCO2 (on blood gas) 1 <sup>28</sup> Admission haemoglobin 1 <sup>13</sup> Anaemia 1 <sup>27</sup> Fibrinolysis 1 <sup>39</sup> Glycaemic Status (not including Hba1c above) Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	Clopidogrel	1 <sup>27</sup>			
Laboratory results       213.28       Hba1c       138         Fasting glucose       113       13         Sodium level       117       14       14         eGFR       121       14       14         Admission creatine       128       14       14         Albuminura       122       14       14         Bilirubin       128       14       14         PCO2 (on blood gas)       128       14       14         Admission haemoglobin       113       133       14         Anaemia       127       139       14       14         Glycaemic Status (not inclumg Hba1c above)       138       138       138         Glycaemic Status (not inclumg Hba1c above)       138       138       138         Insulin resistance       138       138       138		-			
Admission creatinine $2^{13}$ Hba1c $1^{36}$ Fasting glucose $1^{13}$ 1Sodium level $1^{17}$ 1pH below 7.35 $1^{21}$ 1eGFR $1^{22}$ 1Albuminura $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{28}$ PCO2 (on blood gas) $1^{33}$ Admission haemoglobin $1^{13}$ Anaemia $1^{27}$ Fibrinolysis $1^{39}$ Glycaemic Status (not including Hba1c above)Glycaemic variabilityImage: Comparison of the state of the	Laboratory results	- 12 28		. 20	
Fasting glucose117Sodium level117pH below 7.35121eGFR122Albuminura122Bilirubin128PCO2 (on blood gas)128Admission haemoglobin113Anaemia127Fibrinolysis139Glycaemic Status (not including Hba1c above)Glycaemic variabilityImage: Status (not including Hba1c above)138glucose138glucose138glucose138	Admission creatinine	213,28	Hbalc	158	
Source1pH below 7.35 $1^{21}$ eGFR $1^{22}$ Albuminura $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{28}$ Admission haemoglobin $1^{13}$ Anaemia $1^{27}$ Fibrinolysis $1^{39}$ Glycaemic Status (not including Hba1c above)Glycaemic variabilityImage: Glycaemic Variability $1^{34}$ Mean capillary blood $1^{38}$ glucose $1^{38}$	Fasting glucose	117			
pri below 7.531eGFR $1^{22}$ Albuminura $1^{22}$ Bilirubin $1^{28}$ PCO2 (on blood gas) $1^{28}$ Admission haemoglobin $1^{13}$ Anaemia $1^{27}$ Fibrinolysis $1^{39}$ Glycaemic Status (not including Hba1c above)Glycaemic variabilityGlycaemic status (not including Hba1c above) $1^{34}$ Mean capillary bloodImage: Status (not including Hba1c above) $1^{38}$ glucose Insulin resistanceImage: Status (not including Hba1c above) $1^{38}$	Sodium ievei	121			
Albuminura 1 <sup>22</sup> Bilirubin 1 <sup>28</sup> PCO2 (on blood gas) 1 <sup>28</sup> Admission haemoglobin 1 <sup>13</sup> Anaemia 1 <sup>27</sup> Fibrinolysis 1 <sup>39</sup> Glycaemic Status (not including Hba1c above) Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	ocer	1 1 <sup>22</sup>			
Bilirubin 1 <sup>28</sup> PCO2 (on blood gas) 1 <sup>28</sup> Admission haemoglobin 1 <sup>13</sup> Anaemia 1 <sup>27</sup> Fibrinolysis 1 <sup>39</sup> Glycaemic Status (not including Hba1c above) Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	Albuminura	1 1 <sup>22</sup>			
PCO2 (on blood gas) 1 <sup>28</sup> Admission haemoglobin 1 <sup>13</sup> Anaemia 1 <sup>27</sup> Fibrinolysis 1 <sup>39</sup> Glycaemic Status (not including Hba1c above) Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	Bilirubin	128			
Admission haemoglobin 1 <sup>13</sup> Anaemia 1 <sup>27</sup> Fibrinolysis 1 <sup>39</sup> Glycaemic Status (not including Hba1c above) Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	PCO2 (on blood gas)	1 <sup>28</sup>			
Anaemia 1 <sup>27</sup> Fibrinolysis 1 <sup>39</sup> Glycaemic Status (not including Hba1c above)  Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	Admission haemoglobin	1 <sup>13</sup>			
Fibrinolysis 1 <sup>39</sup> Glycaemic Status (not including Hba1c above) Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	Anaemia	1 <sup>27</sup>			
Glycaemic Status (not including Hba1c above) Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	Fibrinolysis	1 <sup>39</sup>			
Glycaemic variability 1 <sup>34</sup> Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	Glycaemic Status (not incl	uding Hba1c above)			
Mean capillary blood 1 <sup>38</sup> glucose Insulin resistance 1 <sup>38</sup>	,		Glycaemic variability	1 <sup>34</sup>	
glucose Insulin resistance 1 <sup>38</sup>			Mean capillary blood	1 <sup>38</sup>	
Insulin resistance 1 <sup>38</sup>			glucose	22	
			Insulin resistance	138	

All the papers used statistical tests to assess the impact of potential risk factors and evaluate their significance. Statistical significance was set at a standard of *p*-value less than 0.05. The majority of the papers, which was 14 in number (40%), used Cox proportional hazards model.

7 papers (20%) had not defined their statistical test, 5 papers (14%) used univariate and multivariate Cox regression analysis, 3 studies (8%) utilised univariate and multivariate analysis, 2 papers (6%) used multivariate analysis, 1 study (3%) used multivariate binary logistic regression, 1 study used Kaplan Meir curves (3%), 1 study used sensitivity analysis (3%) and finally 1 additional study (3%) used parametric and non-parametric tests. No studies considered the application of standardized effect size measures; there was very limited calculation of power sizes, in advance, to identify and appropriate population size for the study.

#### 4. Discussion

The identification of risk factors, following discharge from hospital is an important consideration for patients, clinicians, managers and policy makers. This review represents the first systematic collection and identification of risk factors for mortality in the published research literature. We identify a total of 48 distinct, statistically significant risk factors across 9 categories reported in 35 studies. The most commonly reported risk factor was age, followed by co-morbidity burden. Thirty-seven of the risk factors were only identified as statistically significant in a single research paper. We would argue that this represents a research literature that is at a relatively early stage of maturity, in considering this important topic area.

The quality of studies identified was relatively high, with acceptable sample sizes, albeit frequently lacking a power-calculation for the results reported. The statistical tests used were acceptable, with the majority using Cox proportional hazard models. The small number of papers not defining the statistical test used was however concerning. A large proportion of the extracted articles represented conference abstracts rather than full research papers. These conference abstracts are typically shorter, lack full methodological detail and often do not undergo such rigorous peer review. This again supports the argument that the research literature in this area is at an early stage of maturity.

The results presented in this paper can be compared to a similar review that considered risk factors, specifically for readmission, when patients with diabetes are discharged from hospital.<sup>7</sup> In the review, considering readmission, a significantly larger number of studies were reported (82 studies compared to 35) and 72 distinct risk factors were identified, in comparison to the 48 statistically significant risk factors identified here. There is a higher proportion of conference abstracts within the mortality articles, as compared to the readmission articles, and the mortality articles included fewer reports of prospective studies, compared to the readmission papers. These comparisons, therefore, contrast the early state of the research literature for mortality risk factors with a more complete picture seen relating to risk factors, for readmission. Readmission and postdischarge mortality are both important negative outcomes, in the context of discharge from hospitals. Clinicians, managers and policy makers are motivated to reduce both outcomes. However, it is more typically avoiding readmission that is associated with financial incentivisation for clinical providers. This incentivisation, alongside readmission typically happening sooner than mortality events, may have led researchers more towards conducting readmission rather than mortality studies. However, mortality is undoubtedly a vitally important consideration for all those involved with the discharge process and it is important that adequate research resource is directed towards this outcome.

The strengths of this research include the PRISMA approach to reporting, the use of Keshav's 5Cs approach to quality assessment and the level of detail in data collection. There are however a number of limitations that should be considered. The research only considers papers published in the English Language; there may be other risk factors identified in other studies that are published in different languages. Furthermore, the study only considers papers published over the last 6 years.

6

# **ARTICLE IN PRESS**

T. Mukherjee et al. / Journal of Diabetes and Its Complications xxx (xxxx) xxx

This ensures that all risk factors identified are relevant to current medical practice, although it is possible that previously identified risk factors may be also identified. Finally, the search term used to identify discharge from hospital was only "discharge," this is a relatively universally accepted term for when a patient leaves hospital following an inpatient admission, however it is possible that a very small number of articles used an alternative descriptor and therefore the results should be interpreted with awareness of this.

There is a lot of scope and future work that can be recommended, based on this systematic review. The identified significant risk factors can be stratified according to their effectiveness in predicting mortality in type 2 diabetes patients, following their discharge from hospitals. These will highlight patients who are most vulnerable and need special attention. Additionally, available EHR based predictive tools, such as "deep learning" models that use machine learning techniques and could potentially be used for risk prediction of mortality in such patients, could be found out. Following this step, the feasibility of the chosen predictive tools can be examined and validated. Such evaluated tools for risk prediction can be integrated within the EHR system, to predict the risk of mortality post hospital discharge tailored for each patient who has type 2 diabetes.

#### 5. Conclusions

Mortality, following hospital discharge, is necessarily an important outcome of relevance to patients, carers, clinicians and policymakers. This review is the first systematic collection of risk factors identified for mortality for patients being discharged from hospital with diabetes. The review demonstrates that the literature is at an early stage of maturity, particularly in comparison to the literature considering risks factors for readmission following discharge. This research is particularly important for the future development of risk prediction models that can support the better identification of patients at most risk, and the tailoring of support strategies to individual patient needs in an evidence-based manner.

#### Funding

Dr. Tim Robbins receives funding through a PhD Studentship at WMG, University of Warwick.

Professor Theodoros N. Arvanitis is partially funded by HDR UK. HDR UK is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. HDR-3001.

#### **Declaration of competing interest**

This is to declare that all authors have no conflicts of interest to declare and all funding has been noted in the manuscript.

#### Acknowledgment

The authors would like to thank WMG, University of Warwick for Dr. T. Robbins' PhD studentship and HDR UK for partially funding Prof. T. N. Arvanitis. HDR UK is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust.

#### References

- Valent F, Tonutti L, Grimaldi F. Does diabetes mellitus comorbidity affect in-hospital mortality and length of stay? Analysis of administrative data in an Italian Academic Hospital. Acta Diabetol 2017;54:1081-90.
- Nirantharakumar K, Marshall T, Kennedy A, Narendran P, Hemming K, Coleman J. Hypoglycaemia is associated with increased length of stay and mortality in people with diabetes who are hospitalized. Diabet Med 2012;29:e445-8.
- Savage M, Dhatariya K, Kilvert A, Rayman G, Rees J, Courtney C, et al. Diabetes UK position statements and care recommendations: joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med 2011;28:508-15.
- Akiboye F, Adderley N, Martin J, Gokhale K, Rudge G, Marshall T, et al. Impact of the diabetes inpatient care and education (DICE) project on length of stay and mortality. Diabetic Medicine 2019;37(2):277-85.
- Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, et al. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013;15:194-202.
- Wells BJ, Jain A, Arrigain S, Yu C, Rosenkrans WA, Kattan MW. Predicting 6-year mortality risk in patients with type 2 diabetes. Diabetes Care 2008;31:2301-6.
- Robbins TD, Keung SLC, Sankar S, Randeva H, Arvanitis T. Risk factors for readmission of inpatients with diabetes: a systematic review. J Diabetes Complications 2019;33 (5):398-405.
- Soeken KL, Prescott PA, Herron DG, Creasia J. Predictors of hospital readmission: a meta-analysis. Eval Health Prof 1991;14:262-81.
- Philbin EF, DiSalvo TG. Prediction of hospital readmission for heart failure: development of a simple risk score based on administrative data. J Am Coll Cardiol 1999;33: 1560-6.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9.
- Keshav S. How to read a paper. ACM SIGCOMM Computer Communication Review 2007;37:83-4.
- Abdelhamid YA, Plummer MP, Finnis ME, Biradar V, Bihari S, Kar P, et al. Long-term mortality of critically ill patients with diabetes who survive admission to the intensive care unit. Crit Care Resusc 2017;19:303.
- Arnold SV, Spertus JA, Jones PG, McGuire DK, Lipska KJ, Xu Y, et al. Predicting adverse outcomes after myocardial infarction among patients with diabetes mellitus. Circ Cardiovasc Qual Outcomes 2016;9:372-9.
- 14. Barengo NC, Teuschl Y, Moltchanov V, Laatikainen T, Jousilahti P, Tuomilehto J. Coronary heart disease incidence and mortality, and all-cause mortality among diabetic and non-diabetic people according to their smoking behavior in Finland. Tobacco induced diseases 2017;15:12.
- Beretta MV, Feldman JV, Rodrigues T. Predictor of mortality after hospital discharge in the elderly with type 2 diabetes mellitus—follow-up of two years. Am Diabetes Assoc 2018;67(Supplement 1).
- Buchs AE, Braverman M, Rapoport MJ. Hyperglycemia in diabetic patients in general medicine wards: no independent correlation with in-and out-of-hospital mortality. Sat 2015;15:19.
- Carrasco-Sanchez FJ, Gomez-Huelgas R, Formiga F, Conde-Martel A, Trullas JC, Bettencourt P, et al. Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: findings from the RICA registry. Diabetes Res Clin Pract 2014;104:410-9.
- Chen D-Y, Wang S-H, Mao C-T, Tsai M-L, Lin Y-S, Chou C-C, et al. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: a nationwide cohort study. Int J Cardiol 2015;181:200-6.
- 19. Colombo MG, Meisinger C, Amann U, Heier M, von Scheidt W, Kuch B, et al. Association of obesity and long-term mortality in patients with acute myocardial infarction with and without diabetes mellitus: results from the MONICA/KORA myocardial infarction registry. Cardiovasc Diabetol 2015;14:24.
- Vencio S, Caiado A, Morgental D, Bufaiçal N, Carneiro R, Vencio RC. 21st Brazilian diabetes society congress. 2018.
- Falcone M, Tiseo G, Russo A, Giordo L, Manzini E, Bertazzoni G, et al. Hospitalization for pneumonia is associated with decreased 1-year survival in patients with type 2 diabetes: results from a prospective cohort study. Medicine 2016;95.
- Hsieh Y-M, Lee W-J, Sheu WH-H, Li Y-H, Lin S-Y. Inpatient screening for albuminuria and retinopathy to predict long-term mortality in type 2 diabetic patients: a retrospective cohort study. Diabetol Metab Syndr 2017;9:29.
- 23. Abi Khalil C, Suleiman K, Singh R, Asaad N, Jayyousi A, Al Suwaidi J, et al. Severe obesity, but not overweight, is associated with short-and long-term decreased mortality in patients with type 2 diabetes hospitalized for acute decompensated heart failure: findings from the gulf-care. Circulation 2016;134. p. A12149-A12149.
- 24. Lim W, Goh S-Y, Bee YM, Chan TCE, Tan XHA, Wee Z, et al. High one-year mortality following hospitalization for severe hypoglycemia among patients with diabetes mellitus: findings of a retrospective cohort study at an acute tertiary care hospital in Singapore. Curr Med Res Opin 2019;35:631-5.
- Lysy Z, Fung K, Giannakeas V, Fischer HD, Bell CM, Lipscombe LL. The association between insulin initiation and adverse outcomes after hospital discharge in older adults: a population-based cohort study. J Gen Intern Med 2019;34:575-82.
- 26. Marušić S, Meliš P, Lucijanić M, Grgurević I, Turčić P, Neto PRO, et al. Impact of pharmacotherapeutic education on medication adherence and adverse outcomes in patients with type 2 diabetes mellitus: a prospective, randomized study. Croat Med J 2018;59:290.
- 27. Milionis H, Ntaios G, Papavasileiou V, Spengos K, Manios E, Elisaf M, et al. Aspirin versus clopidogrel for type 2 diabetic patients with first-ever noncardioembolic acute ischemic stroke: ten-year survival data from the athens stroke outcome project. J Stroke Cerebrovasc Dis 2017;26:2769-77.

#### T. Mukherjee et al. / Journal of Diabetes and Its Complications xxx (xxxx) xxx

- Ramaesh A. Incidence and long-term outcomes of adult patients with diabetic ketoacidosis admitted to intensive care: a retrospective cohort study. Journal of the Intensive Care Society 2016;17:222-33.
- Seghieri G, Policardo L, Profili F, Francesconi P, Anichini R, Del Prato S. Hospital incidental diagnosis of diabetes: a population study. J Diabetes Complications 2016;30: 457-61.
- 30. Sharma A, Wu J, Hernandez AF, Felker G, Al-Khatib S, Green J, et al. Comparative effectiveness of primary prevention implantable cardioverter-defibrillators in older adults with diabetes mellitus: insights from the get with the guidelines-heart failure registry. Circulation: Cardiovascular Quality and Outcomes 2018;11. p. A122-A122.
- Snir A, Dabin B, Hyun K, Yamen E, Ryan M, Aliprandi-Costa B, et al. Glycosylated haemoglobin assessment in diabetic patients with acute coronary syndromes. Intern Med J 2016;46:574-82.
- 32. Spanakis EK, Umpierrez GE, Siddiqui T, Zhan M, Snitker S, Fink JC, et al. Association of glucose concentrations at hospital discharge with readmissions and mortality: a nationwide cohort study. The Journal of Clinical Endocrinology & Metabolism 2019;104 (9):3679-91.
- Strele I, Pildava S, Repsa I, Kojalo U, Vilmanis J, Brigis G. Pre-existing diabetes mellitus and all-cause mortality in cancer patients: a register-based study in Latvia. Acta Oncol 2018;57:973-82.
- Timmons JG, Cunningham SG, Sainsbury CA, Jones GC. Inpatient glycemic variability and long-term mortality in hospitalized patients with type 2 diabetes. J Diabetes Complications 2017;31:479-82.
- 35. Trutz J, Babeş A, Babeş K. The importance of the treatment strategy changes in the long-term evolution of type 2 diabetic patients with sub-optimal Glycaemic control after acute coronary syndrome. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 2015;22:29-37.
- 36. Vaduganathan M, Dei Cas A, Mentz RJ, Greene SJ, Khan S, Subacius HP, et al. Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST trial). Am J Cardiol 2014;114:743-50.
- 37. Xanthopoulos A, Giamouzis G, Melidonis A, Kitai T, Paraskevopoulou E, Paraskevopoulou P, et al. Red blood cell distribution width as a prognostic marker in patients with heart failure and diabetes mellitus. Cardiovasc Diabetol 2017;16:81.

- Xing Z, Zhang L, Liu Z, He P, Yang Y, Wulasihan M. Prognostic value of glucose metabolism for non-ST-segment elevation infarction patients with diabetes mellitus and single concomitant chronic total occlusion following primary percutaneous coronary intervention. Medicine 2017:96(45).
- Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Himmelmann A, et al. Impaired fibrinolysis predicts adverse outcome in acute coronary syndrome patients with diabetes: a PLATO sub-study. Thromb Haemost 2020;23.
- 40. Beretta MV, Dantas Filho FF, Freiberg RE, Feldman JV, Nery C, Rodrigues TC. Sarcopenia and Type 2 diabetes mellitus as predictors of 2-year mortality after hospital discharge in a cohort of hospitalized older adults. Diabetes Research and Clinical Practice 2020;159. (no pagination).
- Xu Z, Tong S, Cheng J, Crooks JL, Xiang H, Li X, et al. Heatwaves and diabetes in Brisbane, Australia: a population-based retrospective cohort study. Int J Epidemiol 2019;48:1091-100.
- 42. Edmonston DL, Wu J, Matsouaka RA, Yancy C, Heidenreich P, Pina IL, et al. Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. Am Heart J 2019;212:101-12.
- 43. Echouffo-Tcheugui JB, Sheng S, DeVore AD, Matsouaka RA, Hernandez AF, Yancy CW, et al. Glycated hemoglobin and outcomes of heart failure (from get with the guide-lines-heart failure). American Journal of Cardiology 2019;123:618-26.
- Wright EA, Graham JH, Maeng D, Tusing L, Zaleski L, Martin R, et al. Reductions in 30day readmission, mortality, and costs with inpatient-to-community pharmacist follow-up. J Am Pharm Assoc 2019;59:178-86.
- 45. Bataille V, Ferrieres J, Danchin N, Puymirat E, Zeller M, Simon T, et al. Increased mortality risk in diabetic patients discharged from hospital with insulin therapy after an acute myocardial infarction: data from the FAST-MI 2005 registry. Eur Heart J Acute Cardiovasc Care 2019;8:218-30.
- 46. Lopez-De-Andres A, Jimenez-Garcia R, Esteban-Vasallo MD, Hernandez-Barrera V, Aragon-Sanchez J, Jimenez-Trujillo I, et al. Time trends in the incidence of longterm mortality in T2DM patients who have undergone a lower extremity amputation. Results of a descriptive and retrospective cohort study. J Clin Med 2019;8.
- Azevedo LC, Choi H, Simmonds K, Davidow J, Bagshaw SM. Incidence and long-term outcomes of critically ill adult patients with moderate-to-severe diabetic ketoacidosis: retrospective matched cohort study. J Crit Care 2014;29:971-7.